期刊文献+

腺病毒介导IL-24联合化疗药物增强对肝癌细胞PLC/PRF/5增殖的抑制 被引量:4

Enhanced inhibitory effect of adenovirus-mediated IL-24 combined with chemotherapy agent on growth of liver cancer cell line PLC/PRF/5
下载PDF
导出
摘要 目的:研究腺病毒介导IL-24基因(Ad.IL-24)与化疗药物联用对肝癌细胞株PLC/PRF/5增殖的抑制作用。方法:用Ad.IL-24分别联合化疗药物氟尿嘧啶(fluorouracil,5-Fu)和表柔比星(epirubicin,EPI)处理培养的肝癌细胞株PLC/PRF/5,MTT法检测细胞增殖抑制率,流式细胞术(FCM)检测细胞周期和凋亡率。结果:10 MOI Ad.IL-24与25μg/ml5-Fu联合应用后72h,PLC/PRF/5细胞增殖抑制率达(67.4±0.58)%,显著高于单用Ad.IL-24组的(46.8±0.74)%和5-Fu组的(29.3±0.60)%(均P<0.05);10MOIAd.IL-24与2.5μg/mlEPI联合应用后72h,PLC/PRF/5细胞增殖抑制率达(72.5±0.92)%,显著高于单用Ad.IL-24组的(46.8±0.74)%和EPI组的(32.2±0.69)%(均P<0.05)。流式细胞术检测结果显示,Ad.IL-24与5-Fu或EPI联合应用明显导致细胞在G2/M期阻滞;Ad.IL-24+5-Fu组细胞凋亡率为(52.15±2.32)%,显著高于单用Ad.IL-24组的(28.36±3.49)%和5-Fu组的(8.27±2.61)%(均P<0.05);Ad.IL-24+EPI组细胞凋亡率为(58.67±1.73)%,显著高于单用Ad.IL-24组的(28.36±3.49)%和EPI组的(11.82±1.91)%(均P<0.05)。结论:Ad.IL-24与5-Fu或EPI联用能显著提高对肝癌细胞株PLC/PRF/5增殖的抑制作用。 Objective: To investigate the inhibitory effect of adenovirus-mediated IL-24 ( Ad. IL-24) combined with fluorouracil (5-Fu) or epirubicin (EPI) on growth of human liver cancer cell line PLC/PRF/5. Methods: Human liver cancer cell line PLC/PRF/5 was treated with Ad. IL-24 combined with 5-Fu or EPI separately. The growth inhibition rate of cells was analyzed by MTY assay ; the cell cycle and apoptosis were detected by flow cytometry (FCM). Results: Three days after combined treatment with Ad. IL-24( 10 MOI ) and 5-Fu(25 μg/ml), the growth inhibitory rate of PLC/PRF/5 cells was (67.4 ± 0.58 ) %, which was significantly higher than that in Ad. IL-24 group ( [ 46.8 ± 0.74 ] %, P 〈 0. 05 ) and 5-Fu group ( [ 29.3 ± 0.60 ] %, P 〈 0.05 ) ; three days after combined treatment with Ad. IL-24 ( 10 MOI ) and EPI ( 2.5 μg/ml), the growth inhibitory rate was (72.5 ±0. 92 ) %, which was also significantly higher than those in Ad. IL- 24 group ( [ 46.8 ±0.74 ] %, P 〈 0.05 ) and EPI group ( [ 32.2 ± 0.69 ] %, P 〈 0.05 ). FCM showed that combined administration of Ad. IL-24 and 5-Fu or EPI remarkably arrested PLC/PRF/5 cells at G2/M phase. The cell apoptotic rate was (52. 15±2.32)% in Ad. IL-24 +5-Fu group, which was significantly higher than those in Ad. IL-24 group ([28.36±3.491%, P〈0.05) and 5-Fu group ([8.27 ±2.611%, P〈0.05). The cell apoptotic rate of was (58.67 ± 1.73) % in Ad. IL-24 + EPI group, which was significantly higher than those in Ad. IL-24 group ( [ 28.36 ± 3.49 ] %, P 〈 0.05) and EPI group ( [ 11.82 ±1.91 ] %, P 〈 0.05 ). Conclusion: Ad. IL-24 combined with 5-Fu or EPI has enhanced inhibitory effect on growth of liver cancer cell line PLC/PRF/5.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2007年第4期338-341,共4页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金项目(No30500477)~~
关键词 白介素24 肝肿瘤 基因治疗 化学疗法 表柔比星 氟尿嘧啶 IL-24 liver neoplasms gene therapy chemotherapy epirubicin fluorouracil
  • 相关文献

参考文献1

共引文献14

同被引文献63

  • 1薛新波,郑建伟,王从俊,陈堃,胡回忆,胡慧,于愿,吴在德.腺病毒介导MDA-7/IL-24选择性促进肝癌细胞的凋亡和增殖阻滞[J].中华肝脏病杂志,2006,14(9):670-675. 被引量:10
  • 2石华,杨俊霞,袁成福,易发平,魏丽丽,刘革力,马永平,宋方洲.HPV-16 E6 siRNA与hIL-24基因联合诱导人宫颈癌Ca Ski细胞的凋亡[J].肿瘤,2007,27(5):348-351. 被引量:3
  • 3Fisher PB. Is mda-7/IL-24 a " magic bullet" for cancer [J]? Cancer Res, 2005, 65(22): 10128-10138. 被引量:1
  • 4Gupta P, Su ZZ, Lebedeva IV, et al. mda-7/IL-24: multifunctional cancer specific apoptosis-inducing cytokine [ J]. Pharmacol Ther, 2006, 111(3) : 596-628. 被引量:1
  • 5Liovet JM. Updated treatment approach to hepatocellular carcinoma [J]. J Gastroenterol, 2005, 40(3) : 225-235. 被引量:1
  • 6Chen WY, Cheng YT, Lei HY, et al. IL-24 inhibits the growth of hepatoma cells in vivo [ J ]. Genes Immun, 2005, 6 ( 6 ) : 493- 499. 被引量:1
  • 7McCormick D, Yu C, Hobbs C, et al. The relevance of antibody concentration to the immunohistological quantification of cell proliferation-associated antigens [ J ]. Histopathology, 1993,22 (6) : 543 -547. 被引量:1
  • 8Yoshiji H, Kuriyama S, Yoshii J, et al. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells [ J ]. Hepatology, 1998, 28 ( 6 ) : 1489- 1496. 被引量:1
  • 9Fomer A, Hessheimer AJ, Isabel Real M, et al. Treatment of hepatocellular carcinoma [ J]. Crit Rev Oncol Hematol, 2006, 60 (2) : 89-98. 被引量:1
  • 10Hemandez-Aleoceba R, Sangro B, Prieto J. Gene therapy of liver cancer [J]. Ann Hepatol, 2007, 6(1) : 5-14. 被引量:1

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部